An interventional study of Dietary Supplement in Stroke, Hypoalbuminemia and Sarcopenia, sponsored by University of Ioannina. Not yet recruiting at 1 site in Greece. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-05-08.
Sponsored by University of Ioannina · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Stroke with a site in Greece — 13 open to participants now, 18 under way, 3 of them phase 3. Stroke · Greece.
Among the 55 studies in Stroke with a site in Greece, this one is the 32nd largest by planned enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2025, is one of 19 with no phase, reaches primary completion later than 16 of the 17 other live ones, and was the 48th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →13 of the 55 studies in Stroke with a site in Greece are open now. Recruiting first, the newest first:
Democritus University of Thrace · Sites in Greece
Ages 18–90
Eli Lilly and Company · Sites in Greece, Argentina, Australia and 35 more countries
Ages 50+
Arnaoutis Stylianos · Sites in Greece
Ages 18+
University of Ioannina · Sites in Greece
Ages 15–70
National and Kapodistrian University of Athens · Sites in Greece
Ages 40–100
A study can be open while its sites in Greece have not opened yet or have stopped. Only those recruiting at a site in Greece →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 920 across the 44 interventional studies, 700 across the 11 observational. Of the 34 that completed or were terminated, 14 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 55 have an industry lead sponsor. The 10 most frequent:
University of Ioannina is the lead sponsor of 53 studies on the registry; 14 are open to participants now.
University of Ioannina has 4 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
2 of the studies in Stroke with a site in Greece that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05494034National and Kapodistrian University of AthensYield of Implantable Cardiac Monitoring Device in Patients With Acute Ischemic Stroke. | 2027-01-01 |
| NCT07936461Democritus University of ThraceFeasibility of Occupation-Based Immersive Virtual Reality for Upper-Limb Rehabilitation After Stroke | 2027-07-20 |
Add all 2 to your calendar (.ics) → With an account.
Among the 55 studies in Stroke with a site in Greece, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Brief Summary: The main objective of this thesis is to investigate the role of nutrition - specifically the administration of protein supplements (single dose and double dose) - in the rehabilitation of stroke patients with low albumin levels in relation to sarcopenia, osteopenia and functional recovery indices. The study will follow a randomized controlled trial design, incorporating clinical observation, analysis of biochemical markers, and assessment of physical and functional parameters. Participants will be randomly assigned to one of the three groups: (1) Group 1, receiving no protein supplementation (control group), (2) Group 2, receiving a single dose of protein supplement and (3) Group 3, receiving a double dose of protein supplement. The intervention will last for at least six weeks or until the biochemical markers of albumin normalize and the patient resumes regular oral intake. Biochemical assessment with be conducted through regular nutritional evaluations including measurement of serum albumin, prealbumin, C - reactive protein, creatinine, blood glucose and glycosylated hemoglobin (HbA1c), urea, electrolytes, urine albumin and additional inflammatory markers. Bone density will be assessed using DEXA, MBSR and hip measurements to determine the potential improvements resulting from the intervention. Muscle mass will be evaluated using whole - body DEXA analysis, while muscle strength and mobility will be assessed through grip strength tests and fine gait assessments. Functional recovery will be evaluated usings standardized tools for activities of daily living (Barthel Index), mental state (Geriatric Depression Scale) and quality of life (SF - 36), as well as mobility and walking tests such as the Timed Up and Go Test and 6 - Minute Walk Test. The collected data will be analyzed using appropriate statistical tools, including comparison models (ANOVA, Mann - Whitney U test) and correlation models (Pearson - Spearman). This research is expected to enhance theoretical knowledge regarding the relationship between nutrition, biochemical markers and rehabilitation outcomes in stroke patients with hypoalbuminemia. More specifically, it aims to explore the underlying mechanisms through which nutrition affects recovery - a field that remains unexplored. Additionally, the anticipated finding may contribute to the development of clinical guidelines and therapeutic approaches for the nutritional management of patients with low albumin levels, promoting personalized nutritional strategies that support effective post - stroke rehabilitation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive one dose of protein supplement daily.
Dietary Supplement: Dietary Supplement
Participants in this arm will receive two doses of protein supplement daily.
Dietary Supplement: Dietary Supplement
no protein supplementation
complete, semi-elemental formula for tube feeding and orla intake based on peptides, in powder form, low in fat (32% of energy), high in MCTs (\>90% of total fat) free of fiber and gluten
Serum Albumin Levels
Change in serum albumin concentration to assess nutritional status and response to protein supplementation.
Time frame: Baseline and every 2 weeks for up to 6 weeks
Muscle Mass (Whole-body DEXA)
Evaluation of changes in muscle mass using DEXA scan.
Time frame: Baseline and at week 6
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for May 2025; primary completion for May 2030, 60 months later.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 60 months is above that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Ioannina